All In Biotech

Free tool

FAERS Monitor: Ontralfy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216190 or its brand name (Ontralfy, Tizanidine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,084

Serious

3,950

56% of reports

Hospitalization

1,985

Death reported

419

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue629
  • headache589
  • nausea518
  • pain497
  • drug ineffective484
  • product dose omission issue462
  • somnolence375
  • diarrhoea366
  • dyspnoea356
  • fall342
  • arthralgia334
  • dizziness334
  • off label use307
  • covid-19299
  • pruritus274

Reports by year received

View as table
YearReports
200443
200527
200637
20073
200848
200947
201035
201181
2012151
201367
201499
2015148
2016221
2017194
2018224
2019294
2020434
2021470
2022862
2023862
2024957
20251,009
2026771

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,075 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
somnolenceSignal3755.55.01,401
covid-19Signal2995.14.5978
product dose omission issueSignal4624.74.31,346
fallSignal3423.12.8477
headacheSignal5892.82.6695
painSignal4972.42.2418
fatigueSignal6292.42.2531
arthralgiaSignal3342.42.1273
pruritusSignal2742.11.9163
dizziness3342.01.8167
nausea5181.91.8246
dyspnoea3561.91.7147
diarrhoea3661.71.5104
drug ineffective4841.11.04
off label use3071.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.